Incidence and survival trends of uncommon corpus uteri malignancies in the Netherlands, 1989-2008

International Journal of Gynecological Cancer

Volumn 22, Issue 4, 2012, Pages 599-606

  Boll, Dorry ^a   Verhoeven, Rob H A ^b   Van Der Aa, Maaike A ^c   Pauwels, Patrick ^d   Karim Kos, Henrike E ^e   Coebergh, Jan Willem W ^b,e   Van Doorn, Helena C ^e  

^a CPRLab   (Netherlands)

^b Eindhoven Cancer Registry   (Netherlands)

^c Integraal Kankercentrum Noord Nederland   (Netherlands)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Carcinosarcomas; Corpus uteri malignancies; Endometrial stromal cell sarcoma; Epidemiology; ESR; Rare cancers; Serous adenocarcinoma

Indexed keywords

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER REGISTRY; CANCER SURVIVAL; ENDOMETRIAL STROMAL CELL SARCOMA; ENDOMETRIOID ADENOCARCINOMA; GYNECOLOGIC CANCER; HISTOPATHOLOGY; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; NETHERLANDS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEROUS ADENOCARCINOMA; UNCOMMON EPITHELIAL ENDOMETRIAL CARCINOMA; UTERUS CANCER;

AGED; CARCINOMA, ENDOMETRIOID; CARCINOSARCOMA; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM GRADING; NETHERLANDS; PROGNOSIS; REGISTRIES; SARCOMA, ENDOMETRIAL STROMAL; SURVIVAL RATE; UTERINE NEOPLASMS;

EID: 84863666772     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318244cedc     Document Type: Review

References (25)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
2. Online Cancer Registry; www.ikc.nl. 2011.
3. De Angelis R, Francisci S, Baili P, et al. The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis. Eur J Cancer. 2009;45:909-930.
4. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-578.
5. Evans T, Sany O, Pearmain P, et al. Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. Br J Cancer. 2011;104:1505-1510.
6. Tavassoli FA, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003.
7. Hermanek P, Hutter R, Sobin L, et al. TNM Atlas. Berlin, Germany: Springer; 1997.
8. Schouten LJ, Hoppener P, van den Brandt PA, et al. Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol. 1993;22:369-376.
9. Wittekind C, Klimfinger M, Sobin LH. UICC global cancer control. In: TNM Atlas. Springer Medizin Verlag. ISBN 3-540-63799-0.
10. Kurman RJ. Blaustein's Pathology of the Female Genital Tract. Springer ISBN 0-387-95203-9.
11. Dickman PW, Sloggett A, Hills M, et al. Regression models for relative survival. Stat Med. 2004;23:51-64.
12. Hendrickson MR, Longacre TA, Kempson RL. Uterine papillary serous carcinoma revisited. Gynecol Oncol. 1994;54:261-263.
13. Amant F, Vergote I, Moerman P. The classification of a uterine sarcoma as 'high-grade endometrial stromal sarcoma' should be abandoned. Gynecol Oncol. 2004;95:412-413.
14. Kato DT, Ferry JA, Goodman A, et al. Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol Oncol. 1995;59:384-389.
15. Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol. 1994;54:264-268.
16. Fader AN, Drake RD, O'Malley DM, et al. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer. 2009;115:2119-2127.
17. Fader AN, Starks D, Gehrig PA, et al. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2009;115:244-248.
18. Havrilesky LJ, Secord AA, Bae-Jump V, et al. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol. 2007;105:677-682.
19. Boruta DM, Gehrig PA, Fader AN, et al. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;115:142-153.
20. Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol. 2004;11:117-142.
21. Bitterman P, Chun B, Kurman RJ. The significance of epithelial differentiation in mixed mesodermal tumors of the uterus. A clinicopathologic and immunohistochemical study. Am J Surg Pathol. 1990;14:317-328.
22. Abeln EC, Smit VT, Wessels JW, et al. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed mullerian tumours. J Pathol. 1997;183:424-431.
23. D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116:131-139.
24. Bergman L, Beelen ML, Gallee MP, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment protocol of liver and endometrial cancer risk following tamoxifen. Lancet. 2000;356:881-887.
25. Hoogendoorn WE, Hollema H, van Boven HH, et al. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. Breast Cancer Res Treat. 2008;112:99-108.